Fig. 2From: Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysisMeta-analysis estimated OS comparing cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy. (a) subgroup of estimation of 2-yr OS; (b) subgroup of estimation of 3-yr OS. OS, overall survivalBack to article page